Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of CT1812 in Healthy Volunteers
NCT02570997Phase 1Completed
- Sponsor
- Cognition Therapeutics, Inc.
- Start
- Sep 2015
- Primary completion
- May 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of zervimesine in Alzheimer's disease (AD) and cognitive impairment (5 arms), sponsored by Cognition Therapeutics, Inc. Primary endpoint: Treatment Emergent Adverse Events up to 35 days. Started Sep 2015; status: completed.
02
Drugs
zervimesine
03
Conditions
Alzheimer's disease (AD)cognitive impairment
Beyond the preview
Go deeper on NCT02570997.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02570997.